Dinutuximab

DB09077ApprovedInvestigationalProtein Based TherapiesGlycolipid Disialoganglioside-directed Antibody

Dinutuximab is an immunotherapeutic agent used in combination with other immunomodulating agents to treat high-risk neuroblastoma in pediatric patients who achieve at least a partial response to prior first-line multiagent, multimodality therapy. Dinutuximab is an IgG1 monoclonal human/mouse chimeric antibody against GD2, a disialoganglioside expressed on tumors of neuroectodermal origin, including human neuroblastoma and melanoma, with highly restricted expression on normal tissues.

Mechanism: Dinutuximab is an IgG1 monoclonal human/mouse chimeric antibody against GD2, a disialoganglioside expressed on tumors of neuroectodermal origin, including human neuroblastoma and melanoma, with highly restricted expression on normal tissues. It is composed of the variable heavy- and light-chain regions of the murine anti-GD2 mAb 14.18 and the constant regions of human IgG1 heavy-chain and kappa light-chain. By binding to GD2, dinutiximab induces antibody-dependent cell-mediated cytotoxicity and complement-dependent cytotoxicity of tumor cells thereby leading to apoptosis and inhibiting proliferation of the tumour.
Curator reviewed
Primary indication: Dinutuximab is indicated, in combination with granulocyte-macrophage colony-stimulating factor (GM-CSF), interleukin-2 (IL-2), and 13-cis-retinoic acid (RA), for the treatment of pediatric patients with high-risk neuroblastoma who achieve at least a partial response to prior first-line...Curator reviewed · 1 structured indication
Formula / weight: C₆₄₂₂H₉₉₈₂N₁₇₂₂O₂₀₀₈S₄₈ · 145000.0 Da
First approval: Canada, 2018 · United States, 2015 · European Union, 2020
Also known as: CHIMERIC ANTI-DISIALOGANGLIOSIDE (GD2) MONOCLONAL ANTIBODY (CH14.18/CHO) · Dinutuximab beta · IMMUNOGLOBULIN G1, ANTI-(GANGLIOSIDE GD2) (HUMAN-MUS MUSCULUS MONOCLONAL CH14.18 HEAVY CHAIN), DISULFIDE WITH HUMAN-MUS MUSCULUS MONOCLONAL CH14.18 LIGHT CHAIN, DIMER · IMMUNOGLOBULIN G1, ANTI-(GANGLIOSIDE GD2) (HUMAN-MUS MUSCULUS MONOCLONAL CH14.18/CHO HEAVY CHAIN), DISULFIDE WITH HUMAN-MUS MUSCULUS MONOCLONAL CH14.18/CHO LIGHT CHAIN, DIMER · Monoclonal antibody ch14.18
Code names: APN-311 · CH-14.18 · CH-14.18-UTC · MAB Ch 14.18
Brand names: Qarziba
Unituxin

Resolves to

Compound

UNII7SQY4ZUD30CAS1363687-32-4ChEMBLCHEMBL3137342KEGGD10559

Clinical / RWD

RxNorm1606274ATCL01FX06

What you can answer from here — as of May 26, 2026

1Protein targetEach mapped to UniProt, with action and pharmacological action

Listed above

1,133Drug interactionsStructured to mechanism, not free text

45Clinical trialsPhase, status and sponsor resolved per trial

1Structured indicationCondition, population, route and combination as fields, not prose

6Marketed productsAcross 4 countries and 3 labellers

1ATC codeIncluding every combination product, plus 20 drug categories

5+ReferencesStructured and connected to the statements they support

Which other approved drugs treat the same conditions as Dinutuximab, and which companies have late-stage candidates in those indications?

Answer this in Biopharma OS Sign in to your account

Create a free account or log in to explore the full data card.

Create Account